← Open Payments lookup

NPI 1902991706: Open Payments

NPI 1902991706. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$1,300 in 65 payments from 9 companies in 2025. Trend: 2023 $2,370 · 2024 $2,535 · 2025 $1,300

Food & beverage: $1,189Education: $111
CompanyPaymentsAmount
Teva Pharmaceuticals USA, Inc.12$327
Alkermes, Inc.10$230
Vanda Pharmaceuticals Inc.15$188
ABBVIE INC.11$176
Janssen Pharmaceuticals, Inc5$110
Neurocrine BioSciences, Inc.4$102
Lundbeck LLC3$68
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)3$65
Otsuka America Pharmaceutical, Inc.2$34

Products named: ARISTADA, VRAYLAR, HETLIOZ, UZEDY, INVEGA SUSTENNA, INGREZZA, REXULTI, AUSTEDO XR.